{"entity":{"id":"loxo-oncology","kind":"company","name":"Loxo Oncology","aka":["Loxo Oncology, Inc.","NASDAQ:LOXO"],"tldr":"Loxo Oncology developed pills aimed at single gene changes that drive some cancers, including selpercatinib for RET-altered cancers and pirtobrutinib for some blood cancers. Eli Lilly bought the company in 2019.","summary":"Loxo Oncology, Inc. (formerly Nasdaq: LOXO), based in Stamford, Connecticut, developed highly selective medicines for cancers driven by a single genetic change that can be found by genomic testing. When Eli Lilly agreed to buy it on 7 January 2019, its portfolio included LOXO-292 (later selpercatinib), an oral RET inhibitor with FDA Breakthrough Therapy designation; LOXO-305 (later pirtobrutinib), an oral BTK inhibitor in phase 1/2 designed to work after resistance to existing BTK inhibitors; Vitrakvi (larotrectinib), a TRK inhibitor developed and sold with Bayer; and LOXO-195, a follow-on TRK inhibitor. Lilly paid USD 235 per share in cash, about USD 8.0 billion, through a tender offer, and the merger was completed on 15 February 2019.","asOf":"2026-11-03","links":[{"label":"Lilly announces agreement to acquire Loxo Oncology (8-K exhibit 99.1, 7 January 2019)","url":"https://www.sec.gov/Archives/edgar/data/1581720/000119312519003083/d674169dex991.htm"},{"label":"Form 8-K: completion of the merger (15 February 2019)","url":"https://www.sec.gov/Archives/edgar/data/1581720/000119312519042505/d664418d8k.htm"}],"tags":[],"related":[],"cancers":["nsclc","thyroid","cll","mantle-cell-lymphoma"],"sections":["targeted-therapy"],"technologies":["kinase-inhibitors"],"targets":["ret","btk","ntrk"],"drugs":["selpercatinib","pirtobrutinib","larotrectinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Lilly's own record is named 'Eli Lilly (incl. Loxo)'; this record holds the company before and at the acquisition. Larotrectinib is linked as a Loxo product because the announcement describes it as developed and commercialised by Loxo with Bayer. Completion on 15 February 2019 is from Loxo's 8-K of that date. No website or founding year is recorded."],"hq":"Stamford, CT","country":"US","companyType":"biotech","stage":"acquired","investors":[],"funding":[{"round":"Acquisition","year":2019,"amountUsd":8000000000,"source":"https://www.sec.gov/Archives/edgar/data/1581720/000119312519003083/d674169dex991.htm","note":"Lilly's announcement of 7 January 2019, filed as exhibit 99.1 to Loxo's 8-K: USD 235.00 per share in cash, approximately USD 8.0 billion"}],"acquiredBy":"eli-lilly"},"route":"/companies/loxo-oncology/","neighbours":{"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"},{"id":"mantle-cell-lymphoma","kind":"cancer","name":"Mantle cell lymphoma","route":"/cancers/mantle-cell-lymphoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"thyroid","kind":"cancer","name":"Thyroid cancer","route":"/cancers/thyroid/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"btk","kind":"target","name":"BTK (Bruton tyrosine kinase)","route":"/targets/btk/"},{"id":"ntrk","kind":"target","name":"NTRK","route":"/targets/ntrk/"},{"id":"ret","kind":"target","name":"RET","route":"/targets/ret/"}],"drug":[{"id":"larotrectinib","kind":"drug","name":"Larotrectinib","route":"/drugs/larotrectinib/"},{"id":"pirtobrutinib","kind":"drug","name":"Pirtobrutinib","route":"/drugs/pirtobrutinib/"},{"id":"selpercatinib","kind":"drug","name":"Selpercatinib","route":"/drugs/selpercatinib/"}],"company":[{"id":"eli-lilly","kind":"company","name":"Eli Lilly (incl. Loxo)","route":"/companies/eli-lilly/"}]}}